Difference between revisions of "PET Amyloid Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
Line 19: Line 19:
==PET Amyloid Meetings/Call Summaries==
==PET Amyloid Meetings/Call Summaries==
*[[Media:09_08_2017_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL.pdf|09.08.2017 QIBA PET Amyloid Biomarker Committee Call Summary]]
*[[Media:08_11_2017_QIBA_Amyloid_Biomarker_Ctte_Call_Summary.FINAL.pdf|08.11.2017 QIBA PET Amyloid Biomarker Committee Call Summary]]
*[[QIBA PET Amyloid Biomarker Committee Call Summaries]]
*[[QIBA PET Amyloid Biomarker Committee Call Summaries]]

Revision as of 17:47, 10 November 2017

Co-chairs: Satoshi Minoshima, MD, PhD; Anne M. Smith, PhD; Dawn C. Matthews, MS, MBA
Secretary: Julie Lisiecki

Project Snapshot

There is a draft Profile, and current outline of the Claim is:

  • SUVr will be the measurand
  • The claim will have two components
1) Cross-sectional: single subject scan
2) Longitudinal: following subject over time

Due to the complexity of having multiple PET Amyloid tracers, a subgroup, the Test-retest Group, has been formed including academics and industry representatives from all of the major PET Amyloid tracer vendors. This group will evaluate the published data on amyloid imaging precision, to determine what level of precision can be claimed in the Profile. The committee’s goal is to have a final draft Profile by December, 2015.

Collaborations: RSNA QIBA is now an affiliate of GAAIN (Global Alzheimer’s Association International Network)

PET Amyloid Meetings/Call Summaries

PET Amyloid BC Call Summaries Archive

PET Amyloid Profile Development

Profile Supporting Material

Working Documents

Reference Materials

Presentations and Reports: